Julian Baines, MBE (aged 54) – Non-Executive Chair
Julian is the Company’s Non-Executive Chair and chair of the Remuneration Committee and the Nomination Committee.
Julian is the chief executive officer of EKF, having assumed the role in December 2009. During his tenure at EKF, he has successfully completed multiple fundraisings and the acquisition and subsequent integration of eight businesses in seven countries, building revenue from zero to over £40 million. Prior to joining EKF, Julian was group chief executive officer of BBI Holdings plc, where he undertook a management buyout in 2000, its AIM flotation in 2004 and was responsible for selling the business to Alere, Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million.
In 2016, Julian was awarded an MBE for services to the life sciences industry.
James McCullough (aged 50) – Chief Executive Officer
James is the Company’s Chief Executive Officer, with primary focus on strategic planning and execution, as well as coordination with key stakeholders.
James has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. His skills include equity and debt capital formation, strategic development and partnerships, executive team structuring, regulatory issues and marketing. James was most recently chief executive officer of Exosome Diagnostics, a venture backed personalised medicine company developing non-invasive liquid biopsy diagnostics in cancer. Exosome Diagnostics has recently been acquired by Bio-Techne Corporation (NASDAQ: TECH). James is also a managing partner of Renwick Capital, LLC (“Renwick”), a management consulting firm specialising in assisting emerging healthcare technology companies with strategic planning and business execution.
James received his B.A. from Boston University and an M.B.A. from Columbia Business School. James is currently Chairman of BalletNext, a performing arts company in New York City. He currently holds Series 79 and Series 63 securities licenses from the Financial Industry Regulatory Authority (“FINRA”) in the US.
Fergus Fleming (aged 51) – Chief Technical Officer
Fergus is the Company’s Chief Technical Officer. Fergus is managing director of FF Consulting Limited and Head of Business Development for Oncomark Limited. Fergus has over 25 years’ experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific, Trinity Biotech plc and EKF. Fergus has extensive experience in design and manufacture of medical device software, in vitro diagnostics instruments and reagents and electromechanical devices. He has extensive experience of managing global projects including clinical research collaborations, product development, acquisition integration and manufacturing site transfers.
Richard Evans (aged 61) – Non-Executive Director
Richard is a Non-Executive Director and chair of the Audit Committee.
Richard qualified as a Chartered Management Accountant in 1983 and holds a Bachelor of Commerce in Business Studies and Law from Edinburgh University and an MBA from INSEAD. Before joining EKF Richard was finance director, general manager and finally global account director at Hitachi Data Systems GmbH. He has also held positions at Fisher Scientific, TRW Seat Belt Systems, Maxtor Corporation, United Technologies Carrier and Abbot Diagnostics GmbH in Germany.
Christopher Mills (aged 65) – Non-Executive Director
Christopher is a Non-Executive Director and member of the Remuneration Committee and the Nomination Committee.
Christopher founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management, which he co-founded in 1993. He is chief executive officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and chief investment officer of Harwood Capital LLP. He is a non-executive director of a number of companies. Christopher was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Christopher is a member of the Remuneration Committee and the Nomination Committee.
Barbara Murphy, MD (aged 53) – Non-Executive Director
Barbara is the Murray M. Rosenberg Professor of Medicine, chair of the Department of Medicine for Mount Sinai and Dean for Clinical Integration and Population Health, and will join the Board conditional upon Admission. Her area of interest is transplant immunology, focusing on the use of high throughput genomic technologies as a means to understand the immune mechanisms that lead to graft injury and loss, with the aim of identifying gene expression profiles and or genetic variants that may be used to predict those at greatest risk.
Dr. Murphy earned her M.B. B.A.O. B.Ch. from The Royal College of Surgeons in Ireland and went on to do an internship at Beaumont Hospital in Dublin. She completed a residency rotation at Beaumont Hospital followed by a fellowship in Clinical Nephrology also at Beaumont Hospital. Dr. Murphy completed her postdoctoral training with a fellowship in Nephrology at Brigham and Women’s Hospital, Harvard Medical School. As part of this she trained in transplant immunology at the Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women’s Hospital, Harvard Medical School. Among her many honours, Dr. Murphy was awarded the Young Investigator Award in Basic Science by the American Society of Transplantation in 2003. In 2005, Dr. Murphy was awarded the Irene and Dr. Arthur M. Fishberg Professor of Medicine at The Mount Sinai Hospital. Then, in 2011, she was named Nephrologist of the Year by the American Kidney Fund. She received the distinguished Jacobi Medallion in 2014. She also received an honorary degree from University College, Dublin, Ireland. In 2016, Dr. Murphy was honored by The Annual Irish America Healthcare & Life Science 50.
Dr. Murphy belongs to a number of professional societies including the American Society of Transplantation and the American Society of Nephrology. Among her numerous achievements, she has held many leadership roles at a national level, including being a member of the board of the American Society of Transplantation, the executive committee of the American Transplant Congress, and chair of Education Committee of the American Society of Transplantation. In 2009 Dr. Murphy was the president of the American Society of Transplantation and in 2016 was elected to council for the American Society of Nephrology.
Erik Lium, PhD (aged 50) – Non-Executive Director, Board Representative of Mount Sinai
Erik is a Non-Executive Director and member of the Audit Committee. He will join the Board conditional upon Admission. Erik will represent Mount Sinai on the Board as part of the ongoing relationship between the Company and Mount Sinai.
Dr. Lium is the executive vice president of Mount Sinai Innovation Partners and is responsible for advancing Mount Sinai’s research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialisation of technologies, and fostering the development of start-ups and joint ventures to advance promising early-stage technologies and enhance Mount Sinai’s research and clinical enterprises. Dr. Lium served as a director of Amathus Therapeutics and is a member of the Investment Review Committee for the Accelerate NY Seed Fund.
Prior to joining Mount Sinai, Dr. Lium served as the assistant vice chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), and the UCSF Principal Investigator for the Bay area National Science Foundation I-Corps node. He held previous positions at UCSF, including assistant vice chancellor of Research and director of Industry Contracts, and director of Business Development for the Diabetes Center & Immune Tolerance Network. Dr. Lium served as president of LabVelocity Inc., an Information Services Company focused on accelerating research and development in the life sciences prior to its acquisition in 2004. He pursued post-doctoral research at UCSF in the laboratory of J. Michael Bishop, MD, and earned a PhD with honours from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein. Dr. Lium holds a BS in Biology from Gonzaga University.
Chirag R. Parikh, MD, PhD (Aged 45) – Non-Executive Director
Dr. Parikh is a Professor of Medicine and the Division Director of Nephrology at Johns Hopkins University. He received his medical degree from Seth G.S. Medical College and KEM Hospital in Mumbai, India and subsequently completed his Nephrology fellowship and a PhD in Clinical Investigation at the University of Colorado Health Sciences Center. Following his fellowship, Dr. Parikh joined Yale University where he was faculty for 12 years and also directed the Program of Applied Translational Research.
Dr. Parikh’s research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of kidney diseases. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh’s research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
Dr. Parikh has published over 250 original articles, which have been cited over 25000 times in the literature. His studies have refined the clinical definitions of perioperative acute kidney injury and hepatorenal syndrome, have developed strategies to reduce kidney discard in deceased donor transplantation, and have advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh’s research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and to improve outcomes in patients with kidney disease.
Dr. Parikh has been the recipient of numerous honors and awards, including the 2017 Young Investigator Award from the American Society of Nephrology. He also was elected to the prestigious American Society of Clinical Investigation in 2018.